UK Nod For Pfizer’s COVID-19 Oral Treatment
Pfizer Aims For Early 2022 To Deliver First Treatment Courses To Great Britain
Pfizer’s Paxlovid is the second take-at-home COVID-19 treatment approved for use in the UK.
You may also be interested in...
Coronavirus Notebook: Pfizer Files Paxlovid In EU, France Updates Treatment Advice As Omicron Proliferates
NRx Pharmaceuticals has again filed for a US emergency use authorization for aviptadil, this time for critically ill patients with no other options. The UK has said that there is currently no need to give a second booster vaccine.
US regulators have granted emergency authorization to the antiviral molnupiravir but only for use when "alternative COVID-19 treatment options authorized by the FDA are not accessible or clinically appropriate."
The US FDA’s Christmas gift was the authorization of the first oral pill for treatment of mild-to-moderate COVID-19; Pfizer expects to have 30 million doses of Paxlovid available by mid-2022.